Inclusion Criteria:  Patient > 18 years old Patient naive from anti-EGFR treatment (gefitinib, erlotinib, afatinib, cetuximab panitumumab, osimertinib, alectinib et crizotinib, etc). NSCLC (non-small cell lung cancer) patients eligible to anti-EGFR as first line treatment (gefitinib, erlotinib,afatinib, etc) Colorectal cancer patients eligible to anti-EGFR as first line treatment (cetuximab, panitumumab,….) Head and Neck/ENT (Ear, Nose Troat) cancer patients eligible to anti-EGFR as first line treatment (cetuximab,…) Signed informed consent Social security affiliation  Exclusion Criteria:  Pregnant or Breastfeeding patient Patient in age to procreate without an efficient contraceptive method Patient with previous experience of allergic or irritative contact dermatitis to components of the studied product Patient with dermatologic conditions that cannot permit the study of skin toxicity of anti-EGFR Patients under radiotherapy 8 days prior the inclusion date Patient under immunotherapy 8 days prior the inclusion date Patient with local or systemic antibiotic treatment for acne 8 days prior the inclusion date Patient with antihistamines treatment 8 days prior the inclusion date Patients taking NSAIDs or corticoids as chronic medication or that took NSAIDs or corticoids 5 days prior the inclusion date Participation to another interventional study Patient with an altered ECOG (Eastern Cooperative Oncology Group) state ( >2) Patient deprived of liberty or subjected to guardianship Impossibility to track and follow patient for geographical, social or psychiatric reasons.